A new AI diagnostic tool developed by researchers at Stanford Medicine can detect early-stage lung cancer on CT scans with 96 percent accuracy, outperforming the average radiologist's detection rate of 82 percent in clinical trials involving 15,000 patients.
The system identifies subtle nodule characteristics that are often invisible to the human eye, particularly in patients with dense lung tissue or existing scarring. It provides risk scores and highlights suspicious areas, allowing radiologists to focus their attention on the most critical findings.
The FDA has granted the tool breakthrough device designation, and the developers expect full clearance by the end of 2026, potentially saving thousands of lives through earlier detection.
